BLOOD PRESSURE VARIABILITY AS A FACTOR OF BETTER CARDIOPROTECTIVE EFFICACY OF RENAL DENERVATION

Aim: to study the cardioprotective efficacy of renal denervation in patients with normal and increased blood pressure variability.

Material and Methods. Initially, at 6 and 12 months after renal denervation 84 patients were evaluated by 24-h blood pressure, Doppler echocardiogram and cardiac contrast-enhanced magnetic resonance imaging. Retrospectively, all patients were divided into two groups: the 1^st — with normal (SSD<15 mm Hg, n=28) and the 2nd — with high 24-h blood pressure variability (SSD≥15 mm Hg, n=56).

Results. Left ventricular mass reduced in the 2^nd group at 6 month by 6.9% (p=0.036), at 12 month by 9.6% (р=0.029). By magnetic resonance imaging in the 2^nd group left ventricular mass reduced at 12 month by 15.2% (р=0.010), volume of subendocardial damage — by 28.8% (р=0.039). There were no changes in the 1st group.

Conclusion. After renal denervation left ventricular hypertrophy and subendocardial damage reduce better in patients with high blood pressure variability than in normal.

resistant hypertension, cardioprotective efficacy, blood pressure variability, subendocardial damage, renal denervation

1. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., Christiaens T., Cifkova R., De Barker G., Dominiczak A., Galderisi M., Grobbee D. E., Jaarsma T., Kirchhof P., Kjeldsen S. E., Laurent S., Manolis A. J., Nilsson P. M., Ruilope L. M., Schmieder R. E., Sirnes P. A., Sleight P., Viiqimaa M., Waeber B., Zannad F. Task Force Members. Guidelines 2013 ESH/ESC for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertension. 2013; 31(7): 1281–1357. DOI: 10.1097/01. hjh.0000431740.32696.cc.

2. Rothwell M., Howard C., Dolan E., O’Brien E., Dobson J., Dahlöf B., Sever P., Poulter N. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010; 375(9718): 895–905. https://doi.org/10.1016/j.hjc.2017.12.016.

3. Aalbers J. Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk. Cardiovasc. J. Afr. 2010; 21(2): 115–116.

4. De Jager R. L., Sanders M. F., Bots M. L., Lobo M. D., Ewen S., Beeftink M. M., Böhm M., Daemen J., Dörr O., Hering D., Mahfoud F., Nef H., Ott C., Saxena M., Schmieder R. E., Schlaich M. P., Spiering W., Tonino P. A., Verloop W. L., Vink E. E., Vonken E. J., Voskuil M., Worthley S. G., Blankestijn P. J. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin. Res. Cardiol. 2016; 105(9): 755–762. DOI: 10.1007/s00392-016-0984-y.

5. Böhm M., Mahfoud F., Ukena C., Hoppe U. C., Narkiewicz K., Negoita M., Ruilope L., Schlaich M. P., Schmieder R. E., Whitbourn R., Williams B., Zeymer U., Zirlik A., Mancia G.; GSR Investigators. First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients with Uncontrolled Hypertension. Hypertension. 2015; 65(4): 766–774. DOI: 10.1161/HYPERTENSIONAHA.114.05010.

6. Ripp T. M., Mordovin V. F., Pekarskiy S. E., Ryabova T. R., Zlobina M. Z., Semke G. V., Falkovskaya A. Y., Sitkova E. A., Lichikaki V. A., Krylov A. L. Cardioprotective effects of renal denervation in resistant hypertension: efficiency predictors. Arterial’naya Gipertenziya = Arterial Hypertension. 2014; 20(6): 559–567 (In Russ). DOI: 10.18705/1607-419X-2014-20-6-559-567.

7. De la Sierra A., Pareja J., Armario P., Barrera Á., Yun S., Vázquez S., Sans L., Pascual J., Oliveras A. Renal Denervation vs. Spironolactone in Resistant Hypertension: Effects on Circadian Patterns and Blood Pressure Variability. Am. J. Hypertens. 2017; 30(1): 37–41. DOI: 10.1093/ajh/hpw085.

8. Lang R. M., Badano L. P., Mor-Avi R., Afilalo J., Armstrong A., Ernande L., Flachskampf F. A., Foster E., Goldstein S. A., Kuznetsova T., Lancellotti P., Muraru D., Picard M. H., Rietzschel E. R., Rudski L., Spencer K. T., Tsang W., Voigt J. W. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015; 16(3): 233–270. http://dx.doi.org/10.1016/j.echo. 2014.10.003.

9. Ozel E., Tastan A., Ozturk A., Ozcan E. E. Relationship between Sympathetic Overactivity and Left Ventricular Hypertrophy in Resistant Hypertension. Hellenic. J. Cardiol. 2015; 56(6): 501–506.

10. Schlaich M. P., Kaye D. M., Lambert E., Sommerville M., Socratous F., Esler M. D. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003; 108(5): 560–565. DOI: 10.1161/01.CIR.0000081775.72651.B6.

11. Wittke E. I., Fuchs S. C., Moreira L. B., Foppa M., Fuchs F. D., Gus M. Blood pressure variability in controlled and uncontrolled blood pressure and its association with left ventricular hypertrophy and diastolic function. Hum. Hypertens. 2016; 30(8): 483–487. DOI: 10.1038/jhh.2015.106.

12. Böhm M., Ukena C., Ewen S., Linz D., Zivanovic I., Hoppe U., Narkiewicz K., Ruilope L., Schlaich M., Negoita M., Schmieder R., Williams B., Zeymer U., Zirlik A., Mancia G., Mahfoud F.; Global SYMPLICITY Registry Investigators. Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITYregistry. J. Hypertens. 2016; 34(12): 2480–2486. DOI: 10.1097/HJH.0000000000001085.

13. Parati G., Stergiou G., O’Brien E., Asmar R., Beilin L., Bilo G., Clement D., de la Sierra A., de Leeuw P., Dolan E., Fagard R., Graves J., Head G. A., Imai Y., Kario K., Lurbe E., Mallion J. M., Mancia G., Mengden T., Myers M., Ogedegbe G., Ohkubo T., Omboni S., Palatini P., Redon J., Ruilope L. M., Shennan A., Staessen J. A., van Montfrans G., Verdecchia P., Waeber B., Wang J., Zanchetti A., Zhang Y. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J. Hypertens. 2014; 32: 1359–1366. DOI: 10.1097/HJH.0000000000000221.